{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-000115","form_type":"8-K","ticker":"GNLX","cik":"0001231457","company_name":"GENELUX Corp","filed_at":"2026-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.667933+00:00","generated_at":"2026-05-16T11:47:07.863727+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Genelux appoints Jason Litten as CMO after Paul Scigalla resigns","bullets":["Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.","Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.","Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.","Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-000115","json":"https://secwatch.observer/filing/0001493152-26-000115.json","markdown":"https://secwatch.observer/filing/0001493152-26-000115.md","text":"https://secwatch.observer/filing/0001493152-26-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/0001493152-26-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:47:07.863727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}